{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:27:33Z","timestamp":1774020453853,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijantimicag.2024.107095","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T01:33:43Z","timestamp":1705800823000},"page":"107095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study"],"prefix":"10.1016","volume":"63","author":[{"given":"Jorge","family":"Calder\u00f3n-Parra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4836-6779","authenticated-orcid":false,"given":"Andrea","family":"Guti\u00e9rrez-Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6970-7724","authenticated-orcid":false,"given":"Gerard","family":"Ronda-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa Mart\u00edn","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2019-6783","authenticated-orcid":false,"given":"Helena","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"R\u00f3denas-Baquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Paniura-Pinedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Lozano-Llano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilduara","family":"Pintos-Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1189-1120","authenticated-orcid":false,"given":"Ana","family":"Fern\u00e1ndez-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ramos-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mu\u00f1ez-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ijantimicag.2024.107095_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107095_bib0008","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0017","article-title":"Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0023","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2023.06.007","article-title":"COVID-19 in hospitalized solid organ transplant recipients in a nationwide registry study","volume":"134","author":"Moreno-Torres","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107095_bib0001","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkac256","article-title":"Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge","volume":"77","author":"Piccicacco","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107095_bib0002","doi-asserted-by":"crossref","first-page":"e2402","DOI":"10.1002\/rmv.2402","article-title":"Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis","volume":"32","author":"Amani","year":"2022","journal-title":"Rev Med Virol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107095_bib0003","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/jcm12030864","article-title":"Use of Monoclonal antibodies in immunocompromised patients hospitalized with severe COVID-19: A retrospective multicenter cohort","volume":"12","author":"Calder\u00f3n-Parra","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107095_bib0004","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/jac\/dkac253","article-title":"Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19","volume":"77","author":"Lafont","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107095_bib0005","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107095_bib0006","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2022.05.013","article-title":"Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses","volume":"40","author":"Lyudovyk","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107095_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: A systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107095_bib0010","doi-asserted-by":"crossref","first-page":"e14006","DOI":"10.1111\/tid.14006","article-title":"Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19","volume":"25","author":"Jabr","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0011","series-title":"Criteria to assess the administration of new antiviral therapeutic alternatives against SARS-CoV-2 infection (in order of prioritization","year":"2021"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107095_bib0012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2021.11.007","article-title":"ESCMID COVID-19 living guidelines: drug treatment and clinical management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107095_bib0013","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0014","series-title":"Update on the epidemiological situation of SARS-CoV-2 variants in Spain [Internet]","year":"2023"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107095_bib0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmi.2022.11.002","article-title":"The unique COVID-19 presentation of patients with B cell depletion: author's response","volume":"29","author":"Belkin","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107095_bib0016","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cmi.2022.10.025","article-title":"Re: \u201cthe unique COVID-19 presentation of patients with B cell depletion\u201d by Belkin et al","volume":"29","author":"M\u00fa\u00f1ez-Rubio","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107095_bib0018","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0019","first-page":"1","article-title":"Persistent SARS-CoV-2 PCR positivity despite anti-viral treatment in immunodeficient patients","volume":"6","author":"Chan","year":"2023","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107095_bib0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40164-022-00307-9","article-title":"Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection","volume":"11","author":"Wada","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ijantimicag.2024.107095_bib0021","article-title":"COVID-19 Genomics UK (COG-UK) Consortium, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","author":"Cox","year":"2022","journal-title":"Nat Rev Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792400013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792400013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:46:45Z","timestamp":1760377605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792400013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S092485792400013X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107095","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107095"}}